#USA #San Diego #Parkinson's #BrainXell #BXT-110

BrainXell Therapeutics Unveils Promising Data for Parkinson's Therapy

BrainXell Therapeutics, a pioneering leader in biotechnology, has recently announced significant scientific achievements pertaining to its innovative therapy, BXT-110, designed to combat Parkinson's disease (PD). The company is gearing up to present these promising preclinical data at notable forums this month, including the Cell Symposia | Gene and Cell-Based Therapies Progress in Clinical Translation and the Society for Neuroscience Annual Meeting.

Parkinson's disease stands as one of the most prevalent neurodegenerative disorders, characterized by a gradual loss of midbrain dopaminergic neurons within the substantia nigra region of the brain. These neurons are crucial for dopamine production, playing a vital role in motor control, mood regulation, and various cognitive functions. Given their significance, restoring these neurons has become a primary objective in Parkinson’s disease therapy, making BrainXell's approaches particularly noteworthy.

Katherine Vega Stultz, the CEO of BrainXell, highlighted, "Our work embodies innovation in iPSC technology, marking a pivotal moment for our company. The presentations of our data underscore our commitment to advancing science, innovation, and our profound knowledge of iPSC biology and neuronal differentiation. This groundbreaking research unveils our capacity to spearhead iPSC-derived therapies that possess the potential to transform the lives of patients suffering from neurodegenerative diseases. We are thrilled to develop BXT-110 as a possible treatment avenue for Parkinson's disease."

The research presented provides a glimpse into BrainXell's systematic approach in generating a robust and scalable pathway for BXT-110, which is derived from autologous midbrain dopaminergic progenitor cells (mDAPs). By utilizing both donor and patient-derived iPSC lines, the research team successfully produced highly enriched mDAPs, exhibiting considerable consistency across various biological markers. Encouragingly, in vivo studies revealed excellent graft survival rates and notable functional recovery in a rodent model, showing positive effects as early as 12 weeks post-implantation and maintained efficacy for six months.

These impressive findings for BXT-110 position it as a viable and effective candidate for personalized cell therapy, laying a promising foundation for future development aimed at potentially modifying the disease course of Parkinson's. As the company progresses, it hopes to achieve IND-enabling studies to propel BXT-110 forward, evolving the landscape of treatments available for Parkinson's patients.

About BrainXell Therapeutics

Located in San Diego, California, BrainXell Therapeutics operates as a division of BrainXell, Inc., focusing on cutting-edge regenerative cell therapies, primarily targeting neurodegenerative diseases. The company's initiatives are built on the pioneering research of Dr. Su-Chun Zhang, who serves as the Advising Chief Scientific Officer. The commitment to innovation and research excellence at BrainXell underscores its vision for creating impactful interventions for disorders like Parkinson's disease.

BrainXell’s recent endeavors were supported by funding from the California Institute for Regenerative Medicine (CIRM), an agency dedicated to advancing regenerative medicine by funding transformative research in stem cell and gene therapy. For more detailed information about their groundbreaking work, visit www.brainxell.com.